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Abstract
In acute stroke patients, penumbral tissue is non-functioning but potentially salvageable within a time window of variable
duration and represents target tissue for rescue. Reperfusion by thrombolysis and/or thrombectomy can rescue penumbra and
improve stroke outcomes, but these treatments are currently available to a minority of patients. In addition to the utility of
Glasgow Oxygen Level Dependent (GOLD) as an MRI contrast capable of detecting penumbra, its constituent perfluorocarbon
(PFC) oxygen carrier, combined with normobaric hyperoxia, also represents a potential acute stroke treatment through improved
oxygen delivery to penumbra. Preclinical studies were designed to test the efficacy of an intravenous oxygen carrier, the
perfluorocarbon emulsion Oxycyte® (O-PFC), combined with normobaric hyperoxia (50% O2) in both in vitro (neuronal cell
culture) and in vivo rat models of ischaemic stroke. Outcome was assessed through the quantification of lipid peroxidation and
oxidative stress levels, mortality, infarct volume, neurological scoring and sensorimotor tests of functional outcome in two in vivo
models of stroke. Additionally, we investigated evidence for any positive or negative interactions with the thrombolytic recom-
binant tissue plasminogen activator (rt-PA) following embolus-induced stroke in rats. Treatment with intravenous O-PFC +
normobaric hyperoxia (50% O2) provided evidence of reduced infarct size and improved functional recovery. It did not exacer-
bate oxidative stress and showed no adverse interactions with rt-PA. The positive results and lack of adverse effects support
human trials of O-PFC + 50% O2 normobaric hyperoxia as a potential therapeutic approach. Combined with the diagnostic data
presented in the preceding paper, O-PFC and normobaric hyperoxia is a potential theranostic for acute ischaemic stroke.
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Introduction
The concept of BTime is Brain^ emphasises that in general,
human brain tissue becomes irreversibly damaged rapidly
after arterial occlusion, with an estimated 1.9 million neurons
dying every minute following occlusive stroke [1]. Following
positive individual trials of intravenous recombinant tissue
plasminogen activator (rt-PA) [2, 3], meta-analysis of all
randomised trials of rt-PA [4] has confirmed that treatment
within 4.5 h of symptom onset increased the odds of reducing
disability leading to an improved ability to perform daily ac-
tivities independently, with earlier treatment within this time
window associated with a greater absolute benefit. An abso-
lute increased risk of early death from intracranial haemor-
rhage of about 2% was outweighed by an absolute increase
in disability-free survival of about 10% for patients treated
within 3 h and about 5% for patients where treatment delay
was between 3 and 4.5 h. More recent randomised trials of
second-generation mechanical thrombectomy devices have
shown improved clinical and functional outcomes, within a
time window of approximately 6 h from stroke onset, in pa-
tients with anterior circulation large artery strokes, who are
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less successfully treated with rt-PA [5]. Most recently, benefit
has been shown for both treatment with intravenous throm-
bolysis among patients with stroke of uncertain onset time
when magnetic resonance imaging is used to define probable
onset within the preceding 4.5 h, [6] and for thrombectomy up
to 24 h after symptom onset when patients are selected on the
basis of brain imaging findings that indicate a small volume of
irreversibly damaged tissue in addition to a large artery occlu-
sion [7, 8]. Currently a minority of patients are able to receive
thrombolysis and/or thrombectomy. Access to thrombectomy
in most countries requires transfer to specialist endovascular
treatment centres from primary stroke centres that can initiate
thrombolysis, and secondary transfer is associated with signif-
icantly longer onset-to-treatment times compared to those able
to access endovascular treatment centres directly [9]. The pro-
portion of patients with imaging patterns consistent with ben-
efit from delayed thrombectomy is uncertain, but it is thought
to represent a minority of Bslow progressing^ patients [10].
There is therefore considerable potential benefit for a treat-
ment that could extend penumbral survival. Since tissue death
following ischaemic stroke occurs principally because of a
lack of tissue oxygen, improved oxygen delivery to penumbra
could have a beneficial influence on stroke outcome.
Perfluorocarbons (PFCs) are fluorinated hydrocarbons
with respiratory gas-carrying capacity superior to that of
haemoglobin [11]. They are hydrophobic in nature and there-
fore are emulsified for intravenous use as in vivo oxygen
carriers. PFCs increase tissue oxygenation through their abil-
ity to effectively decrease the plasma gap through which ox-
ygen must travel to reach the red blood cells (RBCs) and/or
vascular endothelium [12]. Because of their small particle
size, PFC emulsions penetrate capillaries within ischaemic
and hypoperfused microcirculation, supplying oxygen, re-
moving carbon dioxide, reinstituting aerobic metabolism,
and possibly restoring flexibility of erythrocytes stiffened by
acidosis [13].
Two major mechanisms underlie the efficacy of PFCs for
oxygen transport [12]. Firstly, they have a high capacity to
dissolve respiratory gases including oxygen rather than bind-
ing them like a ligand. They load and unload oxygen twice as
fast as haemoglobin, since gases are exchanged by simple
diffusion down a partial pressure gradient. Pure PFCs can
dissolve approximately 2.5 times the amount of oxygen than
an equivalent volume of whole blood. Secondly, once emul-
sified, PFC particle size is very small (approximately 0.2 μm
compared to ~ 7–8 μm for human erythrocytes), enabling bet-
ter infiltration through the microcirculation and thus improv-
ing oxygen supply to tissue where perfusion of RBCs is re-
stricted. Therefore, PFCs offer the possibility of oxygenating
and thereby supporting penumbral tissue during the critical
hours following stroke.
PFC’s ability to deliver oxygen to hypoxic tissue, along
with the paramagnetic properties of oxygen and the different
effects of oxy- and deoxyhaemoglobin on the blood oxygen
level dependent (BOLD) T2* signal has been utilised to iden-
tify penumbral tissue in series of studies by our group [14–21].
These unique characteristics make PFCs potential agents with
dual diagnostic [14] and therapeutic properties: providing an
efficient carrier for paramagnetic oxygen and enhancing oxy-
gen delivery to hypoxic brain tissue through any remaining
plasma flow.
A number of published preclinical studies support the po-
tential benefit of oxygenated PFCs in traumatic brain injury
(TBI). Following fluid percussion injury, treatment with
Oxygent (a second-generation PFC emulsion) combined with
100% inhaled oxygen for up to 4 h, improved both brain
oxygen tension as well as mitochondrial oxidative activity
[22]. In separate studies, Oxygent administration resulted in
a significant increase in brain oxygen tension and a substantial
reduction (41%) in the volume of posttraumatic brain damage
[23].
The pharmacodynamic properties of Oxycyte® (a third-
generation PFC emulsion) during haemodilution and brain
injury have been investigated in rodents. Using experimental
models of haemodilution, administration of intravenous
Oxycyte resulted in an enhancement of tissue oxygenation at
the microcirculatory level andmaintained blood oxygen levels
following significant blood loss [24] and effective tissue oxy-
genation in ischaemic states in rats and hamsters [25–27].
Oxycyte has been evaluated in rodent models of lateral fluid
percussion brain injury [28], contusive spinal cord injury [29,
30] and permanent middle cerebral artery occlusion [26]
where it was shown to exert a neuroprotective effect in the
early phase of brain ischaemia and improve brain oxygena-
tion. After traumatic brain injury in rats, Oxycyte improved
cognitive recovery and reduced hippocampal neuronal cell
loss and traumatic axonal injury [28]. Treatment with
Oxycyte significantly enhanced spinal cord grey and white
matter preservation following spinal cord injury as well as
increasing spinal cord oxygenation [30].
Given the relatively large body of research in the literature
dating back to the late 1960s, it is clear that PFCs have gen-
erated a great deal of interest for their potential use in a variety
of potential indications, related to their oxygen carrying prop-
erties in vivo. Over recent years, our group has focussed on
exploiting the superior oxygen carrying properties of PFCs
towards the development of novel MRI-based imaging tech-
niques to identify ischaemic penumbra following an oxygen
challenge [14, 19]. Through this work, we have demonstrated
the enhancement of our Glasgow Oxygen Level Dependent
(GOLD) diagnostic imaging techniques to identify the meta-
bolic penumbra in a rodent stroke model following intrave-
nous Oxycyte (O-PFC) and hyperoxia. Regions identified as
penumbra were shown to display maintained glucose metab-
olism. Successful translation of GOLD imaging could provide
a significant advancement in the management of acute stroke
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patients by identifying those most likely to benefit from treat-
ment irrespective of time from stroke onset.
With evidence of the ability to preserve penumbra from our
diagnostic studies [14], we designed this program of studies to
more rigorously investigate the therapeutic potential of O-
PFC and hyperoxia in the acute stroke setting. These studies
test the hypothesis that the administration of O-PFC in com-
bination with an extended period of normobaric hyperoxia
(50% O2) will exert beneficial effects on stroke outcome and
oxidative stress levels in rodent stroke models.
Material and Methods
PFC emulsion O-PFC was supplied by Tenax Therapeutics
Inc. The perfluorocarbon drug substance is perfluoro(t-
butylcyclohexane) (or FtBu), a saturated alicyclic perfluoro-
carbon, with a molecular formula of C10F20 and a molecular
mass of 500.08. The finished emulsified intravenous drug
product contains 60% w/v FtBu.
Animals in the control groups were administered an equiv-
alent volume of saline.
In Vitro Experiment
Rat neuronal cells (B50 neuroblastoma cells, European
Collection of Cell Cultures, UK) were maintained in
Dulbecco’s minimal essential medium supplemented with
10% (v/v) foetal bovine serum (FBS), 2 mmol/l L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin. Twenty-four
hours after plating, cells were exposed to 9 h hypoxia (1% O2,
5% CO2, balance N2) and serum deprivation followed by 24 h
reoxygenation in complete media in either standard atmo-
spheric air with 5% CO2 or hyperoxic (50% O2, 5% CO2,
balance N2) conditions ± 10% (v/v) O-PFC. Cell lysis was
then carried out.
Lipid Peroxidation Assay
A spectrophotometr ic assay (Tebu-Bio, UK) for
malondialdehyde (MDA) was used to determine lipid perox-
idation levels as per the manufacturer’s instructions. The
MDA and hydroxyalkenal determination protocol was used
and absorbance was measured at 586 nm in a spectrophotom-
eter. All readings were normalised for protein using a BCA
protein assay kit (Pierce).
Rodent In Vivo Studies
This manuscript has been written in accordance with the
ARRIVE guidelines (http://www.nc3rs.org.uk/arrive). All
experiments were performed on adult male Sprague Dawley
(SD) (intraluminal filament model, studies 1–3; n = 197, 335.
1 ± 22.6 g) or Wistar (embolic stroke model, study 4; n = 32,
332.8 ± 21.4 g) rats obtained from Harlan, UK. Animals were
randomly allocated to the study group using an online random
list generator (https://www.random.org/). Investigators
performing analysis to determine infarct volume were
blinded to treatment allocation.
In Vivo Rat Stroke Models
General anaesthesia was induced in all in vivo stroke studies
with 5% isoflurane in nitrous oxide mixed with oxygen (70%
N2O:30% O2). All surgeries were carried out under aseptic
conditions. Following induction of anaesthesia, animals had
oropharyngeal intubation and maintenance of anaesthesia
through mechanical ventilation (approximately 3.0 ml stroke
volume) with 2.5% isoflurane and N2O:O2. Prior to induction
of stroke N2O:O2 was changed to medical air supplemented
with ~ 5% O2 (26% O2: normoxia), delivered at a rate of
approximately 60 breaths per min for all in vivo stroke surgery
procedures. In animals administered hyperoxia, this was in-
duced by increasing the balance of O2:medical air until a read-
ing of 50% O2 was confirmed by an oxygen monitor connect-
ed to the anaesthetic outlet leading to the animal.
Body temperature was maintained at 37 °C ± 0.5 °C. A
femoral vein was cannulated with polythene tubing (Portex,
Smiths Medical, UK: external diameter 0.96 mm; internal
diameter 0.58 mm) for administration of O-PFC or saline.
Prior to recovery, the cannula was removed from the femoral
vein with the small incision being repaired using diathermy.
Intraluminal Filament Model for Permanent and Transient
MCAO
Middle cerebral artery occlusion (MCAO) was induced with
an intraluminal filament. A 3.0 uncoated nylon filament with a
heat-induced bulb at the tip (approximately 0.3 mm in diam-
eter) was advanced along the left internal carotid artery for
approximately 20–21 mm from the bifurcation of the external
carotid artery until resistance was felt. For transient MCAO,
the filament was removed following the predetermined occlu-
sion time, the small incision in the vessel was sealed using
diathermy, enabling restoration of blood flow. The animal was
subsequently recovered from anaesthesia. For permanent
MCAO, the filament was secured in position using ties around
the internal carotid artery prior to recovery.
Embolic Stroke Model
Blood Clot Preparation Twenty-four to 72 h prior to stroke
induction, a blood clot was prepared from a donor rat. Blood
was drawn from the femoral artery into a saline filled PE50
cannula, left to clot at room temperature for 2 h and stored at
4 °C for up to 72 h. When required, the clot was flushed from
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the cannula into sterile saline and a uniform section of ~
30 mm was drawn into a new PE50 cannula and then pushed
into a PE10 cannula, which was attached to the PE50. The clot
was cut to required size within the PE10 cannula (26 ± 2 mm)
for injection through the internal carotid artery.
Embolic Stroke Surgery The model of embolic stroke
employed was modified from a method previously described
[31]. MCAO was induced through the advancement of the
PE10 cannula containing the clot into the left internal carotid
artery. When the tip of the cannula was approximately 1–
2 mm proximal to the origin of the middle cerebral artery,
the clot was injected in 75 μl saline. Rats were transferred
immediately to the MRI scanner, and successful MCAO was
confirmed from the initial diffusion-weighted image (DWI)
scan. Heart rate and rectal temperature were continuously re-
corded (AcqKnowledge, Biopac Systems, CA, USA) during
scanning.
Neurological Assessment
In all studies, functional outcome following stroke was
assessedwith an 18-point sensorimotor assessment [32] where
a high score is indicative of improved outcome (studies 1–4).
In addition, the adhesive label removal test was employed to
assess sensorimotor function (study 2). The time taken for the
rat to both contact and remove the adhesive label from both
paws was measured [33].
Magnetic Resonance Imaging
MRI data were acquired using a Bruker Pharmascan 7 T/
30 cm system with a gradient coil (internal diameter =
121 mm, 400 mT/m) and a 72 mm birdcage resonator.
Following stroke surgery, anaesthetised rats were placed in
the MRI rat cradle and the head was restrained using tooth
and ear bars. A four-channel rat brain phased-array surface
coil was placed above the rats head and secured. A pressure
sensor was attached for respiratory monitoring and core body
temperature was maintained at 37 ± 0.5 °C using a rectal ther-
mocouple and a temperature controlled water jacket.
Diffusion-weighted imaging was employed to assess acute
brain injury associated with embolic stroke (in vivo study 4).
For quantitative determination of the apparent diffusion coef-
ficient (ADC), a multishot spin-echo (echo planar imaging
(EPI)) diffusion-weighted scan was used (TE, 22.9 ms; TR,
4000.0 ms, 2 averages, matrix, 96 × 96 mm; FOV, 25 ×
25 mm2; 3 directions, x, y, z; B values, 0, 1000 s/mm2, 8
contiguous coronal slices of 1.5-mm thickness, 4-shot EPI).
For image analysis, quantitative ADC maps (mm2/s) were
generated for each of the eight contiguous coronal slices
throughout the forebrain. Subsequent analysis of ADC maps
was carried out using ImageJ software. Quantitative ADC
maps in units of square millimetre per second were prepared
and a reduction of 16.5% in the ADC of the mean contralateral
value (excluding ventricles) was used as a threshold to deter-
mine ischaemic lesion volume [34].
T2-weighted imaging was employed to assess infarct vol-
ume 24 h (studies 3 and 4) or 7 days (study 2) after stroke
using a RARE T2-weighted sequence (TE 100 ms, TR
5000 ms, rare factor 8, 2 averages, 256 × 256 matrix,
98 μm × 98 μm in-plane resolution, slice thickness
0.75 mm). The area of infarct was summed over all slices
where infarcted tissue was evident. This was multiplied by
slice thickness to calculate total infarct volume, which was
corrected for brain swelling [35].
H2O2 Assay
Levels of oxidative stress were measured by quantifying hy-
drogen peroxide (H2O2) activity present in brain tissue sam-
ples taken from the ischaemic cortex of animals selected from
in vivo studies 3 and 4. An Amplex Red peroxide assay
(Invitrogen, UK) was used as per manufacturer’s instructions.
Experimental Protocols
Four in vivo stroke studies were carried out as follows: a
transient intraluminal filament model of MCAO (t-MCAO)
was employed for dose optimisation (study 1); efficacy assess-
ment of O-PFC + hyperoxia was carried out in tMCAO (study
2) and in permanent MCAO (p-MCAO) (study 3); investiga-
tion of potential interactions with rt-PA was carried out in a
model of embolus-induced stroke (study 4).
Study 1—O-PFC Dose Optimisation
Under general anaesthesia, t-MCAO was induced in SD rats
using the intraluminal filament model. Reperfusion was in-
duced by subsequent removal of the filament after 90 min.
10 min prior to reperfusion, animals were randomly assigned
to the following (n = 4–5 per group): (1) normoxia (1ml saline
i.v. plus air); (2) hyperoxia (1 ml saline i.v. plus 50% O2); (3)
1.5 ml/kg O-PFC i.v. + 50% O2; (4) 3.0 ml/kg O-PFC i.v. +
50%O2; (5) 4.5 ml/kg O-PFC i.v. + 50%O2; and (6) 6.0 ml/kg
O-PFC i.v. + 50% O2. On recovery from anaesthesia,
hyperoxia (50% O2) was maintained (groups 2–6) for 48 h
in an oxygen tent, and thereafter, animals were returned to
room air until termination (72 h). Group 1 was recovered in
air. Neurological scoring was carried out at 72 h using an 18
point neurological score. The animals were then terminated
with an anaesthetic overdose and infarct volume assessed on
fresh coronal brain slices (6 × 1.5 mm slices) stained with
TTC and corrected for brain swelling [36].
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Study 2—Efficacy of O-PFC + Hyperoxia in a t-MCAO
Model
SD rats received 60 min intraluminal filament-induced
MCAO. Ten minutes prior to reperfusion, animals were ran-
domly assigned to the following (n = 16 per group): (1)
normoxia (1 ml saline plus air); (2) hyperoxia (1 ml saline
plus 50% O2); (3) 3.0 ml/kg O-PFC i.v. + 50% O2; and (4)
6.0 ml/kg O-PFC i.v. + 50% O2. On recovery from anaesthe-
sia, hyperoxia (50%O2) was maintained (groups 2–4) for 48 h
in an oxygen tent, and thereafter, animals were returned to
room air until termination at day 7. Group 1 was recovered
in air. Assessments of functional recoveryweremade at days 3
and 7 poststroke using an 18-point neurological score.
Sensory and motor function was assessed at days 0, 3 and 7
using the adhesive label test [29]. When performing this test,
each rat was monitored for up to a maximum of 3 min with
times noted for both contact and removal of the adhesive.
Final infarct size was measured at day 7 from T2-weighted
MRI scans.
Study 3—Efficacy of O-PFC Plus Hyperoxia
in a p-MCAO Model
SD rats received intraluminal filament-induced p-MCAOwith
a 24 h endpoint. To inform on the minimum effective dose for
clinical translation, a dose of 1.5 ml/kg O-PFC was included
in this study. The therapeutic time window was also investi-
gated by adding groups where initiation of treatment was de-
layed. At the relevant time point post-MCAO (indicated be-
low), animals were randomly assigned to one of the following
groups (n = 14 per group): (1) normoxia (saline i.v. + air
starting 60 min post-MCAO); (2) hyperoxia (saline i.v. +
50% O2) starting 60 min post-MCAO; (3) 1.5 ml/kg O-PFC
i.v. + 50%O2 starting 60min post-MCAO; (4) 3 ml/kg O-PFC
i.v. + 50% O2 starting 60 min post-MCAO; (5) hyperoxia (sa-
line i.v. + 50% O2) starting 3 h post-MCAO; (6) 1.5 ml/kg O-
PFC i.v. + 50% O2 starting 3 h post-MCAO; and (7) 3 ml/kg
O-PFC i.v. + 50% O2 starting 3 h post-MCAO. On recovery
from anaesthesia, hyperoxia (50% O2) was maintained
(groups 2–7) for 24 h in an oxygen tent. Group 1 was recov-
ered in air. An 18-point neurological score [32] was carried
out at 24 h poststroke followed by infarct volume measure-
ment from T2-weighted MRI scans. The animal was subse-
quently terminated and the brain was removed. The ipsilateral
hemisphere was dissected free, and the cortical tissue was
separated. This tissue was snap frozen in liquid nitrogen and
stored at − 80 °C for analysis of oxidative stress. This was
done using an Amplex® Red Hydrogen Peroxide/Peroxidase
Assay to measure levels of hydrogen peroxide in the ischae-
mic cortex of brain tissue from animals (n = 5) selected at
random from each group.
Study 4—Investigation of Safety of O-PFC
and Hyperoxia in Combination with rt-PA in an
Embolic Stroke Model
Embolic Stroke Model—Blood Clot Preparation
Adult male Wistar rats were used for this study. The prepara-
tion of the blood clot and the embolic stroke surgery was
performed as described above with the femoral vein also being
cannulated for administration of O-PFC and rt-PA.
Treatment
Treatment was initiated at approximately 75 min following
introduction of blood clot and baseline DWI scanning to con-
firm evidence of early ischaemic damage (6 animals with no
hyperintensity on DWI scans were excluded from the study).
Animals were randomly assigned to one of the following
groups (n = 8 per group): (1) 3 ml/kg saline + normoxia; (2)
3 ml/kg O-PFC + hyperoxia (50% O2); (3) 0.9 ml/kg rt-PA +
normoxia; (4) 0.9 ml/kg rt-PA + 3 ml/kg O-PFC + hyperoxia
(50% O2). In groups receiving rt-PA, the first 10% of the dose
was given as a bolus with the remaining dose infused over
45 min. In group 4, treatment with O-PFC and hyperoxia was
commenced immediately prior to rt-PA. At the end of the
scanning protocol, animals were returned to the operating the-
atre for removal of the femoral cannula and recovery from
anaesthesia. In groups 2 and 4 where treatment included
hyperoxia, this was maintained for 24 h in an oxygen tent.
Groups 1 and 3 were recovered in air. An 18-point neurolog-
ical score [32] was carried out at 24 h poststroke followed by
infarct volume measurement from T2 MRI scans. The animal
was subsequently terminated and the brain was removed. The
ipsilateral hemisphere was dissected free, and the cortex was
separated and snap frozen in liquid nitrogen and stored at −
80 °C for analysis of oxidative stress using the Amplex® Red
Hydrogen Peroxide/Peroxidase Assay to measure levels of
hydrogen peroxide in the ischaemic cortex of brain tissue from
animals (n = 5) selected at random from each group.
Statistics
In vitro experiments were performed in triplicate on ⩾ 3 inde-
pendent occasions and analysed by unpaired Student’s t test.
Comparison of final infarct size and label contact and removal
time between in vivo groups was analysed using one-way
analysis of variance (ANOVA) with Bonferroni’s posttests
for multiple comparisons. Comparison of 18-point neurolog-
ical score data between in vivo groups was analysed using a
Kruskall–Wallis non-parametric test with Dunn’s posttests for
multiple comparisons. Comparison of changes in lesion size
(study 4) over time and between treatment groups was
analysed using a repeated measures (mixed model) ANOVA
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with Bonferroni’s posttests. Data in figures and tables are pre-
sented as mean ± SD.
Results
In Vitro Model of Hypoxia and Reoxygenation
In vitro studies in a neuronal cell line showed that, as expect-
ed, MDA levels increased after exposure to hypoxia.
Treatment with O-PFC (10% v/v) during reoxygenation sig-
nificantly reduced levels of lipid peroxidation irrespective of
whether reoxygenation was delivered with normoxic or
hyperoxic (50%) O2 levels (Fig. 1).
In Vivo Study 1—Dose Optimisation
This study demonstrated no reduction in infarct size (Fig. 2a)
using hyperoxia alone compared to the normoxia control
(normoxia, mean lesion size = 95.7 ± 68.6 mm3n = 5;
hyperoxia, mean lesion size = 115.0 ± 57.1 mm3, n = 4).
Infarct volumes were smaller in the 1.5 and 3 ml/kg O-
PFC + hyperoxia groups (27.8 ± 21.9 mm3 and 38.6 ±
28.0 mm3, respectively, reaching statistical significance,
p < 0.05) when compared to the saline + hyperoxia group
(115 ± 57.1 mm3) but not the saline + normoxia group (95.6
± 68.6 mm3). However, there was a potential loss of efficacy
in groups receiving higher (4.5 and 6 ml/kg) doses of O-
PFC + hyperoxia, with mean infarct volumes of 52.8 ±
36.1 mm3 and 77.5 ± 37.1 mm3, respectively (Fig. 2a). One
animal died in the saline normoxia group and one in the 6 ml/
kg O-PFC + hyperoxia group. The 18-point neurological
score (Fig. 2b) displayed a trend towards functional improve-
ments with the lower doses (1.5 and 3 mg/kg O-PFC + 50%
O2). Consequently, 3 ml/kg O-PFC + 50% O2 was chosen as
the dose for the larger, more detailed efficacy study using the
t-MCAO (60 min) model, with the 6 ml/kg dose included to
investigate the possible loss of efficacy.
In Vivo Study 2—Efficacy of O-PFC in a Transient
MCAO Model
As illustrated in Fig. 3, infarct size 7 days after t-MCAO was
significantly smaller in the 3 ml/kg O-PFC + hyperoxia group
compared to the normoxic controls (mean lesion size = 36.9 ±
39.0 mm3 compared to normoxic mean lesion size = 66.7 ±
32.2 mm3, p < 0.05, Fig. 3), but not with the higher (6 ml/kg)
dose of O-PFC + hyperoxia. Mortality was higher in the
saline-treated groups (19% in saline + normoxia; 12.5% in
saline + hyperoxia) compared to the O-PFC-treated groups
(6% in both groups).
There was also evidence of improved functional outcome
in the 3 ml/kg O-PFC + hyperoxia-treated group by day 7
(Fig. 4). The adhesive label test, used to asess sensorimotor
function, revealed no significant difference in preference to
contact and remove labels from left and right forepaws at
day 0 (prestroke). By day 3 poststroke, there was a significant
impairment in the ability to contact and remove the label con-
tralateral to stroke in all groups. Data is shown for the lag time
between the ipsilateral and contralateral paw in terms on time
to contact (Fig. 5a) and time to remove (Fig. 5b) the adhesive
label. No difference was observed between the groups on
either day 3 or day 7 in the lag time between ipsilateral and
contralateral paw for times to contact or remove the label (one-
way ANOVAwith Bonferroni’s posttests for multiple compar-
isons). A trend for improved ability to contact the label in the
contralateral paw was observed at day 3 in groups receiving
O-PFC. Likewise, there was a trend towards improved ability
to remove the label using the contralateral paw observed in all
treatment groups vs normoxic control at day 7. As expected,
Fig. 1 The effect of 9-h normoxia or hypoxia (1%O2:5%CO2:balanceN2)
followed by 24 h of normoxia or hyperoxia (50%O2:5%CO2:balanceN2)
on MDA levels in rat B50 neuroblastoma cells in the presence (red bars)
or absence (blue bars) of O-PFC (10% v/v). Results shown are
representative of an experiment performed on three separate occasions
(n = 3). Data are presented as mean ± SEM. **p < 0.01 vs untreated
normoxia/normoxia; #p < 0.01 vs untreated hypoxia/normoxia or untreat-
ed hypoxia/hyperoxia
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there was significant improvement observed in the lag time to
contact in all groups between day 3 and day 7 (paired t test).
However, this improvement from day 3 to day 7 was not
observed in the normoxic control group for the lag time to
remove the label, while it was observed in the three treatment
groups (paired t test).
In Vivo Study 3—Efficacy of O-PFC in a Model
of Permanent MCAO
O-PFC + 50% O2 (1.5 and 3 ml/kg, iv) starting 1 h poststroke
reduced infarct size by 27% and 33%, respectively, compared
to normoxia controls (Fig. 6a). This effect did not reach sta-
tistical significance compared to the normoxia group but was
significantly smaller than the time-matched hyperoxia group
(Fig. 6a). The trend towards efficacy was reduced when treat-
ment was delayed until 3 h poststroke, in the 3 ml/kg O-PFC
group. In the 3-h treatment, delayed animals receiving 1.5 ml/
kg O-PFC + 50% O2 a non-significant 35% reduction in
infarct size was observed, compared to the time-matched
hyperoxia-alone group (Fig. 6a).
A 1–2 point improvement in the 18-point neurological
score in both the 1.5 ml/kg and 3 ml/kg O-PFC + 50% O2
groups compared to normoxic controls did not achieve statis-
tical significance (Fig. 6b).
There was no evidence for increased oxidative stress levels
in cortical samples from the ischaemic hemisphere 24 h after
stroke in the hyperoxia-alone or O-PFC + 50% O2 groups
when compared to the control normoxia group (Fig. 7).
In Vivo Study 4—Investigation of Potential
Interactions Between O-PFC + Hyperoxia and rt-PA
in an Embolic Stroke Model
Variability in the size and location of the infarct in rodent
embolic stroke models is inherently greater than in filament-
induced permanent and transient MCAO models. By
chance, baseline (30 min and 1 h poststroke) DWI lesions,
prior to treatment, were smallest in the rt-PA group (mean
lesion size = 102.5 ± 62.3 mm3) and largest in the control
normoxia group (mean lesion size = 205.9 ± 142.8 mm3)
(Fig. 8a). Consequently, acute growth in the ischaemic le-
sion, from baseline (1 h poststroke) to 3.5 h poststroke, was
used to assess any influence of O-PFC + hyperoxia or inter-
action with rt-PA. The greatest increase in lesion size was in
the untreated control group, but there were no statistically
significant differences in acute lesion growth between
groups (Fig. 8b). Therefore, coadministration of O-PFC +
50% O2 with rt-PA did not display any negative effects with
respect to lesion growth in this embolic stroke study.
There was a suggestion towards an improvement in the 18-
point (non-significant 2–3 point increase) neurological score
Fig. 3 Study 2. Infarct volume was measured at 7 days poststroke
(60 min transient MCAO). Data presented as mean ± SD (n = 16 per
group). Red symbols represent animals that died during the experiment.
*p < 0.05 vs saline + normoxia. One-way ANOVA with Bonferroni’s
multiple comparison test
Fig. 2 Study 1, dose optimisation study in transient (90 min) MCAO
model (n = 4–5 per group). a Infarct volume 3 days after stroke. Red
symbols represent animals that died during the experiment. b Eighteen-
point neurological score 3 days after stroke. *p < 0.05, 1.5 ml/kg and
3.0 ml/kg O-PFC + hyperoxia vs saline + hyperoxia . One-way ANOVA
with Bonferroni correction for multiple comparisons. High score = im-
proved function, red bars indicate median
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in all treatment groups compared to the normoxic control
group (Fig. 8c).
Ischaemic cortex samples, taken 24 h after embolic stroke,
revealed no significant differences in oxidative stress levels
between the treatment groups (Fig. 8d). The highest levels of
H2O2 were recorded in the rt-PA group.
Discussion
Early recanalisation of occluded cerebral arteries by thrombol-
ysis and/or thrombectomy, significantly increases the likeli-
hood of independence after stroke [37]. Reperfusion, and
thereby rescue, of the penumbra is the assumed mechanism.
Fig. 5 Study 2. Adhesive label
test. a Lag time between the
ipsilateral and contralateral paw to
contact the adhesive label at day 3
and 7 poststroke. b Lag time
between ipsilateral and
contralateral paw to remove the
adhesive label at days 3 and 7
poststroke. Data are presented as
mean ± SD. Normoxia (n = 13);
hyperoxia (50% O2) (n = 13);
3 ml/kg O-PFC + 50% O2 (n =
15); 6 ml/kg O-PFC + 50% O2
(n = 14). *p < 0.05 indicates sig-
nificant improvement in the lag
time between day 3 and day 7
(paired t test)
Fig. 4 Study 2. Day 3 (a) and day
7 (b) data for the 18-point neuro-
logical score following 60 min
tMCAO. Red bars indicate medi-
an (n = 16 per group). *p < 0.05,
3 ml/kg O-PFC + hyperoxia vs
saline + normoxia; **p < 0.01,
3 ml/kg O-PFC + hyperoxia vs
saline + hyperoxia, Kruskall–
Wallis non-parametric test with
Dunn’s post hoc multiple com-
parison. High score = improved
function, red bars indicate median
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Potentially salvageable penumbral tissue is hypoperfused and
cells switch to anaerobic metabolism in the absence of oxy-
gen, which thereby significantly reduces their capacity to gen-
erate sufficient ATP for normal function, and consequently
limits survival within the penumbra [38]. Recanalisation of
medium and large intracranial arteries visualised by conven-
tional angiographic imaging methods does not address micro-
vascular tissue perfusion. Rat brain capillaries have an average
diameters of about 2.9 μm [39], and rat RBCs have a diameter
of about 6.5 μm. To pass through these tiny blood vessels,
RBCs require to rearrange their cytoskeleton, which is made
difficult by stiffening consequent to acidosis in ischaemic tis-
sues. O-PFCmicelles however are 1/30th the size of rat RBCs
(diameter of about 200 nm) and are able to penetrate the
smallest blood vessels much more readily than RBCs, en-
abling oxygen delivery to ischaemic tissues.
During the development of GOLD imaging for diagnostic
penumbral detection, we uncovered a serendipitous benefit,
which was support of penumbral tissue, presumably through
the restoration of oxygen levels (Figs. 5 and 6 in [14]). Thus,
O-PFC combined with 50% normobaric hyperoxia (GOLD
therapy) could support the penumbra when administered prior
to reperfusion. This adjunctive therapy could potentially ex-
tend the time windows for rt-PA and thrombectomy, allowing
more patients to be treated. Further, this therapy could poten-
tially be of benefit when early recanalisation is not achieved,
by improving oxygen delivery to penumbra via collateral
flow. We have therefore explored the potential benefits
of maintained normobaric hyperoxia using PFC emulsion
O-PFC and 50% O2 in both permanent and transient
MCAO rodent stroke models and investigated the possibility
of any adverse interactions with rt-PA in an embolic stroke
model.
Overall, the in vivo studies show evidence of efficacy in
infarct size and neurological scores for poststroke treatment
with O-PFC + 50%O2 in clinically relevant models. O-PFC +
50% O2 appears more effective than hyperoxia alone (studies
1, 2 and 3) with a proposed optimum dosing regime of 3 ml/
kg + 50% O2 delivered within 1 h of stroke. This regime in-
duced a significant 45% reduction in infarct size and a 2-point
improvement in neurological score in the tMCAO model,
which induces a surge reperfusion similar to thrombectomy.
To our knowledge, O-PFC + 50% O2 has not previously been
tested in a t-MCAOmodel. Delayed (3 h) administration in p-
MCAO (study 3) and a higher dose of 6 ml/kg in t-MCAO
(studies 1 and 2) were not effective. Infarct size and behav-
ioural outcome are inherently variable in rodent stroke
models, despite standardisation of techniques (e.g. maintain-
ing consistency in the induction of stroke and control of phys-
iological variables under anaesthesia). Perhaps this is the rea-
son that O-PFC + 50% O2 did not consistently achieve statis-
tical significance compared to the control group (normoxia +
Fig. 6 Study 3. a Infarct size measured from T2 MRI scans at 24 h
poststroke in rats exposed to permanent MCAO. Data are presented as
mean ± SD (n = 14 per group). *p < 0.05, 1.5 or 3 ml/kg O-PFC +
hyperoxia vs saline + hyperoxia alone (50% O2), started 1 h poststroke.
One-way ANOVA with Bonferroni’s multiple comparison test. b
Functional outcome assessed with the 18-point neurological score. High
score = improved function, red bars indicate median
Fig. 7 Study 3. H2O2 activity at 24 h after pMCAO, in tissue samples
from the ischaemic cortex of randomly selected animals. Data presented
as mean ± SD (n = 5 per group)
Transl. Stroke Res.
vehicle). In study 3 (pMCAO), the 1.5 and 3 ml/kg (adminis-
tered 1 h poststroke) O-PFC + 50%O2 group infarcts were not
significantly smaller than the control normoxia group, al-
though there was a trend towards smaller infarcts in both O-
PFC treated groups (1.5 ml/kg O-PFC decreased by 27%, p =
0.10, and 3.0 ml/kg O-PFC decreased by 33%, p = 0.06, when
compared to normoxia + vehicle). However, infarct size was
significantly smaller in both O-PFC-treated groups when
compared to the hyperoxia + saline group, which had larger
infarcts and a smaller SD than the control normoxia group. It
was notable that there was a loss of the efficacy observed
when administering O-PFC at 1 h, when delaying treatment
until 3 h poststroke in the permanent MCAOmodel (study 3).
The loss of efficacy is not surprising as penumbra would be
expected to decrease during the hours following MCAO a
model with no reperfusion. However, there was still a trend
towards smaller infarcts in the group receiving the lower dose
of O-PFC administered 3 h post-MCAO. We have previously
shown evidence for existence of penumbra up to 3 h post-
MCAO in this model using advanced imaging techniques
[14]. These data are encouraging, but the true therapeutic po-
tential can only be realised through clinical testing. At present,
there is a very limited literature for PFC studies in stroke
models for comparison. One published study in rat p-
MCAO reported a significant 12% reduction in brain damage
using a very early endpoint after stroke (8 h) with O-PFC
(1 ml/100 g, i.v.) + 100% normobaric O2 administered imme-
diately after induction of stroke [26] while the same study
design replacing normobaric with hyperbaric oxygenation
was ineffective [40]. Alternative PFC emulsions (e.g.
dodecafluoropentane (DDFP), 0.6 ml/kg i.v.) have been tested
in rodent and rabbit stroke models under normoxic conditions.
In rat p-MCAO, infarct size and neurological status were im-
proved within 6 h of stroke after single (1 h poststroke) and
repeated DDFP administration [41] and this regime was sim-
ilarly effective in a rabbit embolic stroke model [42–44].
Encouraging for the field of PFC research in stroke, DDFP
is currently being investigated in an ongoing phase 1b clinical
Fig. 8 Study 4. a Graph showing initial lesion size and lesion growth
during the acute MRI scanning protocol in the embolic stroke model.
Animals were re-scanned using T2-weighted imaging for infarct size at
24 h. Rats were treated with rt-PA (0.9 mg/ml) or 3 ml/kg O-PFC + 50%
O2 ± rt-PA. Treatment was initiated after the first two DWI scans approx-
imately 75 min after stroke onset (dashed vertical line) Data are presented
as mean ± SD (n = 8 per group). bAbsolute change in lesion size for each
group measured from pretreatment baseline (1 h poststroke) to end of
acute scanning protocol (3.5 h poststroke). Data presented as mean ±
SD. c Eighteen-point neurological score (higher score = improved func-
tion, red bar representing median). Animals not surviving to 24 h were
assigned a score of 3. dH2O2 activity at 24 h poststroke, in tissue samples
from the ischaemic cortex of randomly selected animals. Data presented
as mean ± SD
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trial in acute ischaemic stroke patients (NCT02963376;
https://clinicaltrials.gov).
An adverse interaction with rt-PAwould significantly limit
the development of any new acute stroke therapy. Study 4,
conducted to investigate this point, did not uncover any sig-
nificant increase in damage, neurological deficit or incidence
of haemorrhage when rt-PA was combined with O-PFC +
50% hyperoxia in an embolic stroke model. This study was
not powered to detect efficacy, but a rabbit embolic stroke
model combining rt-PA and the PFC DDFP reported reduced
infarct size and improved neurological scores for the combi-
nation compared to rt-PA alone [44].
Delivering oxygen to injured hypoperfused tissues
might raise concerns about the potential to exacerbate ox-
idative stress and reperfusion-related injuries [45].
However, a recent review on normobaric hyperoxia treat-
ment in acute ischaemic stroke reported no evidence for
increase reactive oxygen species or oxidative stress when
normobaric hyperoxia is applied for a short duration (up to
8 h following MCAO): the benefits appear to significantly
outweigh the risks of potential increases in reactive oxygen
species [46]. We found no evidence for increased levels
of oxidative stress in rat models of t-MCAO treated with
O-PFC + 50% O2. No negative interactions on lesion
growth, infarct size or neurological deficit were identified
when O-PFC + 50% O2 was combined with rt-PA in an
embolic stroke model. Furthermore, in vitro experiments
and data from blood and brain tissue samples showed
no evidence of increased oxidative stress following
administration of O-PFC + hyperoxia. These data suggest
that O-PFC + 50% O2 does not put injured ischaemic tissue
at increased risk of reperfusion or oxidative stress-related
injuries.
Clinical stroke imaging studies using various methods
indicate survival of penumbral tissue beyond the current
4.5-h treatment window for rt-PA [47], and recent re-
sults from endovascular (DAWN and DEFUSE-3) and
intravenous thrombolytic (EXTEND) trials support the
efficacy of reperfusion therapy in late time windows
based on imaging signatures. The rate of progression
of tissue damage varies markedly among individuals
[10], leading to the concept of Bfast^ and Bslow^
progressors. In addition to acting as a contrast agent
to image the penumbra, the O-PFC + 50% O2 approach
has the added and unique advantage of potentially
improving penumbral survival. The observations of
possibly smaller infarct volumes among O-PFC-treated
rats compared to control after permanent MCAO in par-
ticular might have relevance to the Bslow progressor^
group in a clinical setting.
Despite the best efforts to power the main efficacy studies
(studies 2 and 3) to detect statistical differences in the key
endpoints, it is likely they remained underpowered due to
the known variability associated with preclinical stroke
models. A further potential limitation relates to a reliance on
neurological scores and one sensorimotor behavioural test to
assess functional outcome. Given the subjective nature of neu-
rological scoring, it is possible that studies could have been
improved by assessing a greater range of sensorimotor tests
with longer end-points, although there remains a lack of con-
sensus on the appropriate tests to be usedwith a large variation
in behavioural tests being used across different preclinical
stroke models. All in vivo studies were performed under gen-
eral anaesthesia which can influence physiological variables
including blood pressure, respiration, blood gases and body
temperature. Anaesthesia is required for stroke surgery and
in vivo imaging in rodent models. However, the confounding
effect of general anaesthesia on the results obtained was
minimised by monitoring physiological variables throughout
the experiments and maintaining these within physiological
limits.
In summary, O-PFC with 50% O2 hyperoxia delivered as
constituents of GOLD penumbral imaging has the potential
to improve stroke outcome and be used as an adjunct for
reperfusion therapy. The translational potential of the
unique, dual diagnostic and therapeutic (theranostic) prop-
erties of this technology will be investigated in clinical tri-
als in acute stroke patients scheduled to begin during the
second half of 2018.
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